Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
Were naïve to AA4500 treatment or had received only one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in AUX-CC-857 ((NCT00528606).
Were judged to be in good health.
Must have participated in protocol AUX-CC-857 (NCT00528606).
You may not be if
Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.
Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
Clareo Health | AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
